ClinicalTrials.gg

Lupus Erythematosus, Cutaneous clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 67 studies for Lupus Erythematosus, Cutaneous across more than 10 countries. 18 are recruiting or about to start. 41 of them are mainly about Lupus Erythematosus, Cutaneous (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Lupus Erythematosus, Discoid too: 87 studies, 20 open.

Status

Completed
30
Recruiting
12
Terminated
9
Active, not recruiting
6
Not yet recruiting
4
Status unknown
2

Phase

Phase 2
26
Phase 1
16
Phase 3
10
Early Phase 1
3

Where

United States
39
Germany
23
Poland
17
Spain
15
Bulgaria
13
China
12

Who develops what

Add Lupus Erythematosus, Cutaneous to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 8 companies, 5 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare InnoCare Pharma, Merck KGaA, Darmstadt, Germany and Xiamen Amoytop Biotech here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PrednisoneRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06625671 · DualityBio Inc. · Phase 2 · live · background · “Prednisone” · registered Sep 2024
Johnson & Johnson11% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
enpatoran☆ Track3 live phase-3 studies: NCT07840287, NCT07332481, NCT07355218Merck KGaA, Darmstadt, Germany
afimetoran☆ Track1 live phase-3 study: NCT07881120Beeline Medicines Corporation

The 2 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.VENT-03 · Ventus Therapeutics U.S., Inc. · Phase 2 main aimNCT07260877 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus — primary endpoint: Evaluate the effect of VENT-03 on the interferon gene signature in the skin · 24 enrolled
  • Mar 2027 est.ICP-488 · InnoCare Pharma Limited · Phase 2 main aimNCT07440537 Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study — primary endpoint: The percentage change of Cutaneous lupus erythematosus disease area and severity index-activity(CLASI-A) relative to the baseline at week 16. · 105 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Lupus Erythematosus, Cutaneous studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

9studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9, phase 3 first

Who these studies take

Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger. 2 (17%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (25%) take healthy volunteers.

Recruiting studies that take each age, of 12
AgeWomenMen
101 (8%)1 (8%)
1812 (100%)12 (100%)
3012 (100%)12 (100%)
4012 (100%)12 (100%)
5012 (100%)12 (100%)
6511 (92%)11 (92%)
759 (75%)9 (75%)
854 (33%)4 (33%)

Across all 67 studies, recruiting or not: 54% stop at 75 or younger and 15% at 65; 3% take children; 1% are for women only and 0% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 67. Browse all 67 → or search them.